Browsing Tag
GRAIL
8 posts
What does Abbott’s Cancerguard AACR data mean for multi-cancer early detection and the $21bn Exact Sciences acquisition?
Abbott presents Cancerguard dual-biomarker MCED data at AACR 2026. What the DETECT-A survival findings mean for ABT, GRAIL, and cancer screening. Read more.
Why Hims & Hers Health’s decision to offer Grail’s Galleri test looks riskier after the U.K. NHS trial miss
Grail’s Galleri cancer test missed a major U.K. NHS trial goal just as Hims & Hers Health began offering it. Find out what this means for investors and screening strategy.
GRAIL stock surges 14% after $110m Samsung deal to expand Galleri test in Asia
GRAIL stock jumps 14% after Samsung's $110M investment and Asia commercialization deal for its Galleri cancer test. Learn how investors are reacting.
Why has ovarian cancer eluded early screening success—and what’s changing now?
Ovarian cancer screening has failed for decades—now new tests like exosome and cfDNA panels are finally changing the story. Find out what’s driving the shift.
Illumina’s stunning victory against EU regulators changes the game for mergers
In a landmark decision that could redefine the boundaries of European merger control, the Court of Justice of…
GRAIL’s new REACH study of Galleri MCED test set to change future of cancer detection for seniors – Find out how
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company renowned for its mission to detect cancer early when it can…
European Commission approves Illumina’s divestment plan for GRAIL
The European Commission, exercising its authority under the EU Merger Regulation (EUMR), has granted approval to Illumina’s proposed…
Illumina to take full ownership of cancer screening company GRAIL in $8bn deal
Illumina acquisition of GRAIL : US sequencing company Illumina has agreed to fully acquire California-based cancer screening company…